For example, among the five countries with the highest number of people with T1D (China, India, the USA, Brazil and Russia), only the USA [12] and Russia [13] have clinical guidelines for T1D patients that include long-acting insulin analogues among the treatment options, under restricted indications. This evidence concerns the gene INS and type 1 diabetes mellitus.